Reti ShaneDr SHANE RETI (National) (remote): Thank you Madam Speaker. It really is a pleasure to speak on this bill tonight. And can I offer heartfelt congratulations to the member for getting his piece of work to this stage and getting his bill through the House. This is a nice piece of work. I did enjoy his walk back through sunscreens through his life. Mine probably starts with QTOL if I look back and work my way forward. And as he correctly pointed out sun risk a feature of several things: clearly exposure to the sun's rays; secondly your ability to protect; and then thirdly as he commented a fair complexion or that genetic predisposition. And interestingly he mentioned that he'd had a number of basal cells and squamous cells removed because of his fair complexion. I caught up with a 40-year-old gentleman about three months ago and he has a syndrome called Gorlin syndrome G-o-r-l-i-n and that's a syndrome where the DNA repair mechanism to the skin is faulty. And at the age of about three they start developing skin cancers basal cells and squamous cells. And he removed his shirt because I've been fascinated in this condition I'd only seen it in books and he was like a patchwork quilt across his back. There must have been 70 incisions where cancers have been removed. Can you imagine that from the age of three or four? And so clearly that genetic predisposition—he could reduce that incidence by being sun smart like the rest of us would be but he particularly is the beneficiary of a sunscreen that is compliant with best practice and compliant with the highest sun protection factor rating possible; so a beneficiary without doubt.I think that this bill looking through the select committee process the 36 submissions I thought all of them added value and I thought there were particularly interesting parts segueing into what the therapeutic products bill may eventually become with discussions around natural products alternative products and this indeed sitting as a cosmetic. I think part of that discovery has exposed other parts of the process. If we look at where this bill is working it's working at performance standards and product claims. It was interesting to note that the manufacturing component currently has no statutory legislation and so that may well be covered in the therapeutic products bill be that good manufacturing practice or whatever manufacturing standard is determined. It's another part of this process that makes it even better.I think interesting also I've mentioned genetic predisposition the fair complexion—this must be one of those slightly unusual health situations where equity for Māori is less applicable because of Māori having a darker complexion. We generally get less melanoma than others. So odd in that respect—beneficial in that respect.I also think there's something interesting going forward to look at how we might measure the effectiveness of this bill as it moves through here tonight. It'd be interesting to have some sort of a snapshot before and after. What impact did the passage of this bill have on sun-induced skin cancers? Hard to determine but you know if there was a 10 percent reduction in skin cancers for no other obvious cause one might reliably point to well maybe it was the passage of good legislation. So it'd be good to snapshot before this bill is actually enabled. And that sort of leads to something which one of the other members has spoken about and that is the ability to monitor compliance for what we're looking to achieve here today. That manufacturers and retailers will adhere to the standards that we're wanting to embody here and how do we monitor that? Who monitors that? That's all been part of the committee discussion certainly under the Fair Trading Act. But it will be interesting to look and see how resources are applied how often how much and what those findings are because that is a large part of what we're looking to do here tonight.So in summary this may be a small bill—ASSISTANT SPEAKER (Hon Jacqui Dean): I call—Hon Members: He's still going.ASSISTANT SPEAKER (Hon Jacqui Dean): Oh sorry Dr—so Dr Reti is finished thank you. No?Hon Member: You cut him off.ASSISTANT SPEAKER (Hon Jacqui Dean): Well I won't cut him off.Dr SHANE RETI: OK well I will be shortly. That's quite OK. I will be shortly. This is as good a bill as it was 30 seconds ago. So I want to commend the member. I really do look forward to applying it in practice. Well done. Thank you Madam Speaker.ASSISTANT SPEAKER (Hon Jacqui Dean): Apologies for the flopping around. Just trying to get our ducks lined up—always an interesting thing.